Plain-English translation of NCT06556485 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
CASTLE-VT is testing whether a preventive catheter ablation procedure — a minimally invasive treatment that targets and treats scarred heart tissue — can help people with severe heart failure and irregular heartbeats avoid worse complications. Half of the participants will receive this preventive treatment, while the other half will receive standard heart failure medications. The trial will follow both groups for 2 years to see if the procedure reduces the need for heart transplants, life support devices, or emergency treatments.
People with severe heart failure often develop dangerous irregular heartbeats that can be life-threatening. Right now, doctors usually wait until these dangerous rhythms happen before treating them. This trial is testing whether treating the scarred tissue in the heart before these rhythms develop could prevent serious complications and keep patients healthier longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive the preventive catheter ablation procedure or continue with standard heart failure medications. The procedure involves a catheter (thin tube) guided to your heart to map and treat scarred tissue while your heart is in a normal rhythm. You will have regular follow-up visits over 2 years to check your heart function, quality of life, and how many dangerous rhythms you experience, allowing researchers to compare how well the two approaches work.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Germany